Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» Urogen
Urogen
UroGen submits new drug application to FDA for UGN-102
Pharmaceutical Business Review
Thu, 01/25/24 - 11:31 am
Urogen
FDA
UGN-102
urothelial cancer
Urogen's Potential First Non-Surgical Therapy for LG-IR-NMIBC Posts Promising Phase 3 Trial Data
Benzinga
Thu, 07/27/23 - 11:35 am
Urogen
clinical trials
UGN-102
non-muscle invasive bladder cancer
bladder cancer
UroGen reports data from Phase IIb trial of bladder cancer treatment
Clinical Trials Arena
Mon, 12/5/22 - 10:51 am
Urogen
clinical trials
UGN-102
bladder cancer
UroGen presses ahead with RTGel after Botox pairing stumbles in overactive bladder trial
Fierce Pharma
Thu, 09/3/20 - 11:52 pm
Urogen
AbbVie
Jelmyto
overactive bladder
AbbVie & UroGen Overactive Bladder Treatment Misses in Phase 2 Trial
Xconomy
Thu, 08/27/20 - 10:22 pm
AbbVie
Urogen
overactive bladder
Allergan
Botox
Covid-19 adds a new danger to drug launches
EP Vantage
Fri, 04/17/20 - 10:46 am
drug launches
pandemic
COVID-19
Esperion
Biohaven
Urogen
UroGen Gets FDA Nod for Low-Grade Upper Tract Urothelial Cancer Drug
Xconomy
Wed, 04/15/20 - 11:27 pm
Urogen
urothelial cancer
FDA
Jelmyto
The Week Ahead In Biotech: Spotlight On ESMO Conference
Yahoo/Benzinga
Sun, 09/22/19 - 11:10 pm
JNJ
daratumumab
Urogen
Rhythm Pharmaceuticals
Anavex
Aravive Biologics
TrovaGene
Incyte
AstraZeneca
Roche
Amgen
Aslan
G1 Therapeutics
GSK
Calithera Biosciences
Seattle Genetics
Immunomedics
Checkpoint Therapeutics
Aileron Therapeutics
Genocea Biosciences
AbbVie
Zymeworks
UroGen, Wave each raise $150M follow-ons
BioCentury
Thu, 01/24/19 - 11:47 pm
Urogen
Wave Life Sciences
As Barrett steps in as CEO, UroGen reports 57% complete response rate for urothelial cancer therapy
BioCentury
Tue, 01/8/19 - 11:44 pm
Urogen
UGN-101
MitoGel
urothelial cancer
Liz Barrett
Why did Liz Barrett turn her back on a top job at Novartis in exchange for the helm of a biotech you never heard of?
Endpoints
Thu, 01/3/19 - 04:10 pm
Liz Barrett
Novartis
Urogen
Upcoming events – Phase III readouts loom for Urogen and Mediwound
EP Vantage
Fri, 12/21/18 - 12:04 pm
Urogen
clinical trials
UGN-101
urothelial cancer
MediWound
NexoBrid
devices
burns